VA
AUPH icon

Vident Advisory’s Aurinia Pharmaceuticals AUPH Stock Holding History

Vident Advisory’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,930
Closed -$190K – 1842
2025
Q4 		$190K Sell
11,930
-4,558
-28% -$64.6K ﹤0.01% 1563
2025
Q3 		$182K Sell
16,488
-144
-0.9% -$1.57K ﹤0.01% 1571
2025
Q2 		$141K Sell
16,632
-12,199
-42% -$97.8K ﹤0.01% 1538
2025
Q1 		$232K Buy
+28,831
New +$234K ﹤0.01% 1375

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vident Advisory's AUPH Position: Q1 2026 in Review

Vident Advisory sold out of Aurinia Pharmaceuticals (AUPH) in Q1 2026, closing a stake of 11,930 shares — an estimated $190K sold.

Vident Advisory first reported a position in AUPH in Q1 2025 and held it in 4 quarters. The position peaked at $232K in Q1 2025. 260 funds tracked by Wall St. Rank hold AUPH as of Q1 2026.

  • Vident Advisory reported no remaining Aurinia Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Vident Advisory sold 11,930 Aurinia Pharmaceuticals shares in Q1 2026, an estimated $190K.
  • Vident Advisory first reported a position in Aurinia Pharmaceuticals in Q1 2025 and held it in 4 quarters.
  • Vident Advisory's Aurinia Pharmaceuticals position peaked at $232K in Q1 2025.
  • 260 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2026.

Based on Vident Advisory's 13F filing for Q1 2026, filed 15 May 2026.